Tanvex BioPharma Inc Net Assets
Tanvex BioPharma Inc net assets. Based on the latest financial reports, Tanvex BioPharma Inc (6541) has net assets worth NT$5.36 Billion TWD (≈ $169.00 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$7.64 Billion ≈ $240.64 Million USD) and total liabilities (NT$2.27 Billion ≈ $71.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Tanvex BioPharma Inc net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$5.36 Billion |
| % of Total Assets | 70.23% |
| Annual Growth Rate | 24.68% |
| 5-Year Change | 103.74% |
| 10-Year Change | 59.36% |
| Growth Volatility | 155.18 |
Net Assets of Tanvex BioPharma Inc (2013–2025)
Net assets of Tanvex BioPharma Inc from 2013 to 2025. This chart illustrates how Tanvex BioPharma Inc's net assets have evolved over time, based on quarterly financial data. See Tanvex BioPharma Inc (6541) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Tanvex BioPharma Inc (2013–2025)
The table below shows the annual net assets of Tanvex BioPharma Inc from 2013 to 2025. For live market cap and overall valuation, see market value of Tanvex BioPharma Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$5.69 Billion ≈ $179.39 Million |
+537.41% |
| 2024-12-31 | NT$893.31 Million ≈ $28.14 Million |
+8.79% |
| 2023-12-31 | NT$821.11 Million ≈ $25.87 Million |
-40.99% |
| 2022-12-31 | NT$1.39 Billion ≈ $43.84 Million |
-50.21% |
| 2021-12-31 | NT$2.79 Billion ≈ $88.05 Million |
+6.64% |
| 2020-12-31 | NT$2.62 Billion ≈ $82.57 Million |
-13.53% |
| 2019-12-31 | NT$3.03 Billion ≈ $95.49 Million |
-28.09% |
| 2018-12-31 | NT$4.21 Billion ≈ $132.79 Million |
+12.42% |
| 2017-12-31 | NT$3.75 Billion ≈ $118.12 Million |
+4.93% |
| 2016-12-31 | NT$3.57 Billion ≈ $112.57 Million |
+146.76% |
| 2015-12-31 | NT$1.45 Billion ≈ $45.62 Million |
+145.57% |
| 2014-12-31 | NT$589.64 Million ≈ $18.58 Million |
+46.08% |
| 2013-12-31 | NT$403.64 Million ≈ $12.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tanvex BioPharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1556449700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Tanvex BioPharma Inc Net Assets Breakdown (December 2025)
Tanvex BioPharma Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$2.65 Billion | 46.52% |
| Other Comprehensive Income | NT$920.29 Million | 16.16% |
| Other Components | NT$17.76 Billion | 311.94% |
| Total Equity | NT$5.69 Billion | 100.00% |
Tanvex BioPharma Inc Competitors by Market Cap
The table below lists competitors of Tanvex BioPharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
centrotherm international AG
F:CTNK
|
$227.62 Million |
|
Asia Cuanon Tech (Shanghai)
SHG:603378
|
$227.66 Million |
|
Dongsung FineTec Co. Ltd
KQ:033500
|
$227.67 Million |
|
Treace Medical Concepts Inc
NASDAQ:TMCI
|
$227.70 Million |
|
Spok Holdings Inc
NASDAQ:SPOK
|
$227.46 Million |
|
Senao International Co Ltd
TW:2450
|
$227.41 Million |
|
RF Capital Group Inc
TO:RCG
|
$227.36 Million |
|
AstroNova Inc
NASDAQ:ALOT
|
$227.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tanvex BioPharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 893,306,000 to 5,693,982,000, a change of 4,800,676,000 (537.4%).
- Net loss of 1,500,157,000 reduced equity.
- New share issuances of 1,264,204,000 increased equity.
- Other comprehensive income increased equity by 1,098,224,999.
- Other factors increased equity by 3,938,404,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-1.50 Billion | -26.35% |
| Share Issuances | NT$1.26 Billion | +22.2% |
| Other Comprehensive Income | NT$1.10 Billion | +19.29% |
| Other Changes | NT$3.94 Billion | +69.17% |
| Total Change | NT$- | 537.41% |
Book Value vs Market Value Analysis
This analysis compares Tanvex BioPharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.03x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | NT$13.42 | NT$27.25 | x |
| 2014-12-31 | NT$16.95 | NT$27.25 | x |
| 2015-12-31 | NT$28.98 | NT$27.25 | x |
| 2016-12-31 | NT$53.26 | NT$27.25 | x |
| 2017-12-31 | NT$54.94 | NT$27.25 | x |
| 2018-12-31 | NT$52.80 | NT$27.25 | x |
| 2019-12-31 | NT$34.87 | NT$27.25 | x |
| 2020-12-31 | NT$28.16 | NT$27.25 | x |
| 2021-12-31 | NT$24.99 | NT$27.25 | x |
| 2022-12-31 | NT$11.49 | NT$27.25 | x |
| 2023-12-31 | NT$6.31 | NT$27.25 | x |
| 2024-12-31 | NT$5.75 | NT$27.25 | x |
| 2025-12-31 | NT$23.27 | NT$27.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tanvex BioPharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -374.13%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.40x
- Recent ROE (-26.35%) is above the historical average (-84.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -74.08% | 0.00% | 0.00x | 1.21x | NT$-339.40 Million |
| 2014 | -80.13% | 0.00% | 0.00x | 1.11x | NT$-531.45 Million |
| 2015 | -57.68% | 0.00% | 0.00x | 1.08x | NT$-980.05 Million |
| 2016 | -34.83% | 0.00% | 0.00x | 1.08x | NT$-1.60 Billion |
| 2017 | -37.60% | 0.00% | 0.00x | 1.06x | NT$-1.78 Billion |
| 2018 | -44.93% | 0.00% | 0.00x | 1.06x | NT$-2.32 Billion |
| 2019 | -75.04% | 0.00% | 0.00x | 1.18x | NT$-2.58 Billion |
| 2020 | -80.29% | -701412.00% | 0.00x | 1.67x | NT$-2.37 Billion |
| 2021 | -55.22% | -28546.26% | 0.00x | 1.69x | NT$-1.82 Billion |
| 2022 | -117.94% | -7325.17% | 0.01x | 2.46x | NT$-1.78 Billion |
| 2023 | -260.27% | -3480.00% | 0.02x | 3.37x | NT$-2.22 Billion |
| 2024 | -154.66% | -3983.94% | 0.01x | 3.06x | NT$-1.47 Billion |
| 2025 | -26.35% | -374.13% | 0.05x | 1.40x | NT$-2.07 Billion |
Industry Comparison
This section compares Tanvex BioPharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,874,950,100
- Average return on equity (ROE) among peers: 6.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tanvex BioPharma Inc (6541) | NT$5.36 Billion | -74.08% | 0.42x | $227.50 Million |
| Apex Biotechnology Corp (1733) | $1.63 Billion | 27.85% | 0.20x | $90.38 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $182.16 Million |
| Panion & BF Biotech Inc (1760) | $1.24 Billion | 2.25% | 1.48x | $131.42 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.77 Billion | 3.40% | 0.54x | $76.34 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.56 Billion | 15.36% | 0.11x | $108.46 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $31.29 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $46.47 Million |
| Medigen Biotechnology (3176) | $6.47 Billion | -10.44% | 0.54x | $139.57 Million |
| Sagittarius Life Science (3205) | $797.37 Million | -11.51% | 0.12x | $93.74 Million |
| Genovate Biotechnology Co Ltd (4130) | $2.12 Billion | 2.19% | 0.18x | $115.03 Million |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicine… Read more